BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cilla N, Dallemagne J, Vanhove M, Stordeur P, Motte S, De Wilde V. Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab. J Hematol 2020;9:84-8. [PMID: 32855757 DOI: 10.14740/jh614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Katsivalis KV, Thomas J. Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura. J Adv Pract Oncol 2021;12:211-5. [PMID: 34109052 DOI: 10.6004/jadpro.2021.12.2.8] [Reference Citation Analysis]
2 Elverdi T, Özer Çerme MD, Aydın T, Eşkazan AE. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 2021;:1-6. [PMID: 34130583 DOI: 10.1080/17512433.2021.1944102] [Reference Citation Analysis]